TaiRx, Inc. (TPEX:6580)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
15.00
+0.05 (0.33%)
May 29, 2026, 1:45 PM CST
Market Cap1.68B -39.2%
Revenue (ttm)27.88M +239.0%
Net Income-221.13M
EPS-2.00
Shares Out 112.12M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume111,179
Open15.05
Previous Close14.95
Day's Range14.75 - 15.20
52-Week Range13.55 - 31.80
Beta0.45
Analystsn/a
Price Targetn/a
Earnings DateApr 17, 2026

About TaiRx

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic dev... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 29
Stock Exchange Taipei Exchange
Ticker Symbol 6580
Full Company Profile

Financial Performance

In 2025, TaiRx's revenue was 27.88 million, an increase of 239.03% compared to the previous year's 8.22 million. Losses were -221.13 million, 59.3% more than in 2024.

Financial Statements